Polyarteritis Nodosa (Cutaneous)

Comprehensive Clinical Guide: Cutaneous Polyarteritis Nodosa (CPAN)

1. Introduction and Overview

Cutaneous Polyarteritis Nodosa (CPAN) represents a localized, non-systemic form of necrotizing vasculitis that primarily affects the medium-sized arteries of the dermis and subcutaneous tissue. Unlike Systemic Polyarteritis Nodosa (PAN), which involves visceral organs such as the kidneys, gastrointestinal tract, and neurological system, CPAN is generally restricted to the skin, though it may occasionally manifest with systemic symptoms such as fever, malaise, and arthralgia.

CPAN is a chronic, relapsing condition that predominantly impacts the lower extremities. While it carries a significantly better prognosis than systemic vasculitis, its clinical course can be debilitating, often characterized by painful nodules, ulcerations, and livedo reticularis. Understanding the distinction between CPAN and systemic variants is the cornerstone of effective management.

2. Deep-Dive: Mechanisms and Pathophysiology

The pathophysiology of CPAN is rooted in a necrotizing vasculitis of the medium-sized muscular arteries. Unlike systemic PAN, which is often associated with Hepatitis B or C infection, the etiology of CPAN is frequently idiopathic, though it has been linked to post-streptococcal infections and other immune-mediated triggers.

The Pathological Cascade

1. Endothelial Injury: The process begins with immune complex deposition or direct endothelial damage within the arterial wall.
2. Inflammatory Infiltration: Neutrophils and mononuclear cells infiltrate the media and adventitia of the vessel.
3. Fibrinoid Necrosis: As the inflammation progresses, the vessel wall undergoes fibrinoid necrosis, leading to arterial occlusion.
4. Ischemia: The resulting narrowing or occlusion of the lumen causes distal ischemia in the dermis and subcutaneous fat, manifesting as the characteristic nodules and ulcers.

Histopathological Characteristics

A biopsy of a CPAN lesion typically reveals:
* Necrotizing vasculitis of medium-sized arteries at the dermal-subcutaneous junction.
* Absence of glomerulonephritis or visceral involvement.
* Leukocytoclastic vasculitis may be present in smaller vessels, but the diagnostic hallmark remains the involvement of the medium-sized muscular arteries.

3. Clinical Indications and Presentation

The clinical diagnosis of CPAN is based on a constellation of physical findings. Because there is no single pathognomonic laboratory test, the diagnosis remains primarily clinical, supported by histopathology.

Standard Clinical Signs

Staging and Grading

While there is no formal "staging" system for CPAN, clinicians typically categorize severity based on the following:
* Mild: Limited nodular lesions without significant ulceration.
* Moderate: Multiple nodules with recurring, superficial ulcerations; localized pain.
* Severe: Deep, chronic, non-healing ulcers; significant systemic inflammatory response (fever, malaise); secondary infection risks.

4. Differential Diagnosis

Distinguishing CPAN from other inflammatory and vascular conditions is critical, as treatment protocols vary significantly.

• Erythema Nodosum: Usually presents as tender, non-ulcerating nodules on the shins; histopathology shows septal panniculitis without vasculitis.
• Systemic Polyarteritis Nodosa: Must be ruled out via imaging (angiography) or organ function tests (renal/liver panels).
• Nodular Vasculitis (Erythema Induratum): Often associated with tuberculosis; involves the posterior lower legs.
• Livedoid Vasculopathy: Characterized by painful, purpuric lesions that evolve into ivory-white scars (atrophie blanche).
• Septic Emboli: Must be considered in patients with fever and multiple nodules to rule out infective endocarditis.

5. Diagnostic Testing Protocols

To confirm CPAN and exclude systemic involvement, the following diagnostic battery is recommended:

1. Skin Biopsy: An excisional biopsy including the subcutaneous fat is mandatory. Punch biopsies may be insufficient if they fail to capture the medium-sized vessels.
2. Laboratory Baseline:
   • Complete Blood Count (CBC) to check for leukocytosis or anemia.
   • ESR and CRP to assess the systemic inflammatory burden.
   • Hepatitis B and C serology (to rule out secondary systemic vasculitis).
   • Antistreptolysin O (ASO) titers if post-streptococcal etiology is suspected.
3. Vascular Imaging: If there is any clinical suspicion of systemic involvement (e.g., hypertension, abdominal pain), mesenteric angiography or CT angiography (CTA) is required to visualize the renal and visceral arteries.

6. Management and Prognosis

The goal of treatment is to reduce inflammation, manage pain, and prevent ulcer recurrence.

Therapeutic Hierarchy

• First-Line: NSAIDs (e.g., indomethacin or naproxen) for mild disease.
• Second-Line: Colchicine or Dapsone for chronic, recurring cases.
• Third-Line: Systemic corticosteroids (prednisone) for acute flares or severe ulceration.
• Refractory Cases: Immunosuppressants such as methotrexate, azathioprine, or cyclophosphamide are reserved for severe, persistent disease.

Long-Term Prognosis

CPAN generally follows a benign course. While it is chronic and prone to relapse, it does not progress to systemic visceral organ failure. With proper management, the patient’s life expectancy is normal. However, the psychological impact of chronic pain and scarring should not be underestimated.

7. Risks and Contraindications

• Corticosteroid Risks: Long-term use of systemic steroids carries risks of osteoporosis, hyperglycemia, and immunosuppression. Tapering must be slow.
• Dapsone Contraindications: Patients with G6PD deficiency must be screened prior to initiation to avoid hemolytic anemia.
• Surgical Contraindications: Avoid unnecessary debridement of ulcers if active vasculitis is present, as it may exacerbate the inflammatory response.

8. FAQ: Frequently Asked Questions

1. Is Cutaneous PAN the same as systemic PAN?

No. Cutaneous PAN is restricted to the skin and subcutaneous tissue, whereas systemic PAN affects major organ systems like the kidneys and intestines.

2. Can CPAN be cured?

CPAN is a chronic, relapsing condition. While it can be effectively managed and brought into long-term remission, patients may experience flares throughout their lives.

3. Why are skin biopsies often inconclusive?

If a biopsy is too shallow, it may miss the medium-sized arteries located at the junction of the dermis and subcutaneous fat. An excisional wedge biopsy is often required for a definitive diagnosis.

4. What is the role of Streptococcal infection in CPAN?

In children and some adults, CPAN is often a post-infectious manifestation of a preceding streptococcal infection. Treating the underlying infection can sometimes resolve the vasculitis.

5. Does CPAN lead to organ failure?

By definition, CPAN does not involve visceral organs. If a patient develops renal hypertension or gastrointestinal symptoms, the diagnosis must be reconsidered as systemic PAN.

6. Are there specific triggers for a flare?

Triggers vary, but cold exposure, infections (streptococcal), and localized trauma are frequently cited by patients as exacerbating factors.

7. Is smoking a risk factor?

Yes. Smoking is a known vasoconstrictor and can worsen ischemic ulcers and delay the healing process in patients with any form of vasculitis.

8. What is the most effective pain management?

Pain in CPAN can be intense due to nerve involvement (vasa nervorum). NSAIDs are the first-line, but some patients may require gabapentin or tricyclic antidepressants for neuropathic pain.

9. How long do I need to stay on medication?

Treatment duration is highly individualized. Many patients remain on low-dose maintenance therapy (like Colchicine) for months or years to prevent recurrence.

10. Can CPAN affect my pregnancy?

While CPAN is not inherently linked to obstetric complications, the drugs used (e.g., methotrexate) are teratogenic. Consultation with a rheumatologist is essential for family planning.

9. Clinical Summary Table: Quick Reference

10. Conclusion

Cutaneous Polyarteritis Nodosa is a distinct, manageable condition that requires a high index of suspicion and a meticulous diagnostic approach. By differentiating it early from systemic vasculitis, clinicians can avoid unnecessary aggressive therapies while providing targeted, effective care that improves the patient’s quality of life. Constant vigilance for the development of systemic symptoms remains the most important aspect of long-term follow-up for these patients.

Disclaimer: This guide is intended for clinical informational purposes and does not replace professional medical judgment. Always consult current clinical guidelines (such as those from the ACR or EULAR) when managing individual patient cases.